This proposal is for the funding required to staff and operate the Statistical Office of the Gynecologic Oncology Group (GOG), a cooperative research group. It is the function of this office to collect, abstract, code, update, process, analyze and present the data submitted by member institutions. Additionally, the GOG Statistical Office performs follow-up quality control, plays a major role in the design, formatting and randomization of all new protocols, implements interim and final study chairman's reviews, and is the focal point for the preparation of all GOG abstracts and manuscripts for publication. Our principal objective is to manage patient data in an efficient and accurate manner, resulting in timely analyses, logical and appropriate interpretation of results and relevant publications. Inherent in this objective is the continued expansion and application of the Roswell Park Management Information System (RPMIS) to keep pace with the corresponding growth of GOG. Similarly, expanding the intrinsic involvement of study chairmen in the review and analyses of their studies is essential in maintaining the desired quality of data required by GOG standards. The achievement of these goals will have direct bearing upon the future management of patients with gynecologic malignancies. The methodology involved consists of: (a) Involvement of GOG Statistical Office in all phases of study design, conduct, management and interpretation as mandated by GOG Protocol Procedures Manual; (b) Use and expansion of a sophisticated system of direct data entry (RPMIS) featuring video computer terminals; (c) Early determination and implementation of protocol-specific coding on all studies; (d) Continued and more expanded use of computer evaluation sheets (EVL's) which provide a viable vehicle to foster interaction among study chairmen, data abstractor, and statistician; this methodology enables each parotocol to be thoroughly reviewed twice-yearly in order to resolve questions and incorporate comments or suggestions into the patient data. (e) Coordination, monitoring and preparation of all GOG publications via word-processing equipment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA037517-02
Application #
3558165
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1984-07-01
Project End
1988-04-30
Budget Start
1985-05-01
Budget End
1986-04-30
Support Year
2
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Norquist, Barbara M; Brady, Mark F; Harrell, Maria I et al. (2018) Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 24:777-783
Chan, John K; Brady, William; Monk, Bradley J et al. (2018) A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol 150:247-252
Horowitz, Neil S; Larry Maxwell, G; Miller, Austin et al. (2018) Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 148:49-55
Bishop, Erin A; Java, James J; Moore, Kathleen N et al. (2018) Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol 218:109.e1-109.e11
Valicenti, Richard K; Pugh, Stephanie L; Trabulsi, Edouard J et al. (2018) First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy. Int J Radiat Oncol Biol Phys 100:695-701
Aghajanian, Carol; Filiaci, Virginia; Dizon, Don S et al. (2018) A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 150:274-281
Monk, Bradley J; Kauderer, James T; Moxley, Katherine M et al. (2018) A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol 151:422-427
Hensley, Martee L; Enserro, Danielle; Hatcher, Helen et al. (2018) Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol :JCO1800454
Felix, A S; Brasky, T M; Cohn, D E et al. (2018) Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. Int J Cancer 142:1102-1115
Matulonis, Ursula A; Sill, Michael W; Makker, Vicky et al. (2018) A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol :

Showing the most recent 10 out of 484 publications